ARC TALKS Webinar: Clinical Trial Updates for the AL Community скачать в хорошем качестве

ARC TALKS Webinar: Clinical Trial Updates for the AL Community

Kristen Hsu, ARC’s Executive Director of Research, presented the most current updates for the clinical trial landscape, with a focus on AL amyloidosis. Kristen also discussed the direction future research. This webinar was original presented on April 15, 2025. 0:00 — Welcome 4:00 — Introduction 6:40 — What is a Clinical Trial? 7:52 — Clinical Trial Phases 13:00 — What makes a study a good fit for me? 16:09 — AL Amyloidosis Clinical Trial Overview 25:00 — AL Amyloidosis Trials Recruiting in 2025 25:54 — LINKER-AL2 (Relapsed/refractory AL amyloidosis) 30:04 — ENTENTAMIG (Relapsed/refractory AL amyloidosis) 33:17 — NEXICART-2 (Relapsed/refractory AL amyloidosis) 35:53 — AFFIRM-AL (Newly diagnosed AL amyloidosis) 38:58 — Upcoming Milestones for AL Therapies in 2025 43:00 — Future Development for AL Therapies 45:35 — Other Recruiting and Planned Clinical Trials 49:30 — How to Find Clinical Trials 52:48 — Q&A Session 53:37 — How do measurements of “free light chains” relate to disease progression? 56:10 — Which study is appropriate for patients who have already had an autologous stem cell transplant? 57:13 — Could CAR-T cell therapy eventually replace stem cell transplants? 58:08 — What is the timeline between a study concluding and treatments becoming available? 1:00:29 — What is the impact of current federal policy changes on amyloidosis research? 1:03:46 — Conclusion